For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and the formulated version represents a significant change. These innovative therapies protect the transthyretin protein, slowing its harmful build-up and alleviating the severity of the illness. People are now experiencing posi… Read More